RESEARCH ARTICLE


Sustained Intraocular Pressure Elevation After Intravitreal Injection of Bevacizumab and Ranibizumab Associated with Trabeculitis



Matthew Sniegowski, Naresh Mandava , Malik Y Kahook*
Rocky Mountain Lions Eye Institute, Department of Ophthalmology, University of Colorado Denver, Aurora, CO 80045, USA


Article Metrics

CrossRef Citations:
0
Total Statistics:

Full-Text HTML Views: 1115
Abstract HTML Views: 1460
PDF Downloads: 265
Total Views/Downloads: 2840
Unique Statistics:

Full-Text HTML Views: 643
Abstract HTML Views: 666
PDF Downloads: 178
Total Views/Downloads: 1487



© Sniegowski et al.; Licensee Bentham Open.

open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.

* Address correspondence to this author at the University of Colorado Denver School of Medicine, Department of Ophthalmology, 1675 Aurora Ct, Mail Stop F-731, Aurora, Colorado 80045, USA; Tel: 720-848-2500; Fax: 720-848-5014; E-mail: malik.kahook@gmail.com


Abstract

Anti-vascular endothelial growth factor agents are frequently used to treat a variety of ocular neovascular diseases. While agents like bevacizumab and ranibizumab appear to be safe and effective, there have been reports of severe intraocular inflammation as well as sustained elevation of intraocular pressure (IOP) after single or multiple intravitreal injections of these protein-based therapeutics. The true mechanism leading to inflammation and/or sustained spikes in IOP remains unknown. We report a patient with sustained IOP elevation and kerato-precipitates on the trabecular meshwork after multiple injections of both bevacizumab and ranibizumab. We propose that monomer antibodies, aggregated proteins, or other high molecular weight molecules might lead to inflammation in the trabecular meshwork and subsequent elevation in IOP.

Keywords: Bevacizumab, ranibizumab, vascular endothelial growth factor, glaucoma, intraocular pressure, neovascular age-related macular degeneration, trabeculitis, inflammation.